[{"address1": "287 Xiangke Road", "address2": "Pudong New District", "city": "Shanghai", "zip": "201210", "country": "China", "phone": "86 40 0828 5227", "website": "https://www.hspharm.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.", "fullTimeEmployees": 9099, "companyOfficers": [{"maxAge": 1, "name": "Ms. Huijuan  Zhong", "age": 62, "title": "Chairlady, CEO & President", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 2078148, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Aifeng  Lyu", "age": 46, "title": "Executive Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 448134, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yuan  Sun", "age": 36, "title": "Executive Director", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 1009951, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Min  Hu", "age": 46, "title": "VP & CFO", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Chih-Hung  Lee", "age": 63, "title": "Chief of Science Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chuanhe  Xu", "age": 59, "title": "Senior Vice President", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Weiyong  Sun", "age": 52, "title": "Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shengli  Zhong", "age": 55, "title": "Joint Company Secretary & Senior VP", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sze Wai  Tam", "title": "Joint Company Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 1, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 1.88, "dayLow": 1.88, "dayHigh": 1.88, "regularMarketOpen": 1.88, "regularMarketDayLow": 1.88, "regularMarketDayHigh": 1.88, "dividendRate": 0.03, "dividendYield": 0.0145000005, "exDividendDate": 1726790400, "payoutRatio": 0.21360001, "beta": 0.609, "trailingPE": 26.857143, "volume": 100, "regularMarketVolume": 100, "marketCap": 13258850304, "fiftyTwoWeekLow": 1.5, "fiftyTwoWeekHigh": 1.88, "priceToSalesTrailing12Months": 1.0959457, "fiftyDayAverage": 1.88, "twoHundredDayAverage": 1.8117, "trailingAnnualDividendRate": 0.315, "trailingAnnualDividendYield": "Infinity", "currency": "USD", "enterpriseValue": -12237499392, "profitMargins": 0.38966, "floatShares": 1070908059, "sharesOutstanding": 5926040064, "heldPercentInsiders": 0.81754, "heldPercentInstitutions": 0.10005, "bookValue": 4.709, "priceToBook": 0.3992355, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 1.115, "netIncomeToCommon": 4714180096, "trailingEps": 0.07, "enterpriseToRevenue": -1.012, "enterpriseToEbitda": -2.691, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "HNSPF", "underlyingSymbol": "HNSPF", "shortName": "HANSOH PHARMACEUTICAL GROUP CO ", "longName": "Hansoh Pharmaceutical Group Company Limited", "firstTradeDateEpochUtc": 1681219800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f0f9cb77-fbe1-32cf-8c4c-e02ebb40363f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.88, "recommendationKey": "none", "totalCash": 23497648128, "totalCashPerShare": 3.965, "ebitda": 4548109312, "totalDebt": 119672000, "quickRatio": 7.702, "currentRatio": 7.984, "totalRevenue": 12098089984, "debtToEquity": 0.429, "revenuePerShare": 2.042, "returnOnAssets": 0.082609996, "returnOnEquity": 0.18104, "earningsGrowth": 1.107, "revenueGrowth": 0.442, "grossMargins": 0.91013, "ebitdaMargins": 0.37594002, "operatingMargins": 0.39491, "financialCurrency": "CNY", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]